Venrock Adviser, LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$2.06B2026 Q3
Positions34
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.71.0%
What Changed This Quarter?
Top Holdings
ORKA
Oruka Therapeutics
16.8%
ERAS
Erasca
14.3%
SYRE
Spyre Therapeutics
10.8%
KRSA
Korsana Biosciences
7.1%
SVRA
Savara
4.9%
OCUL
Ocular Therapeutix
3.9%
DMRA
Damora Therapeutics
3.7%
DNTH
Dianthus Therapeutics
3.5%
New / Increased
7 new · 7 increased
KRSANEW
Korsana Biosciences
7.1%
DMRANEW
Damora Therapeutics
3.7%
ADRXNEW
Adarx Pharmaceuticals
1.6%
ARVNNEW
Arvinas
0.7%
Entera BioNEW
Entera Bio
0.7%
ERAS
Erasca
14.3%
+12.3%
SVRA
Savara
4.9%
+32.7%
ACHV
Achieve Life Science
2.2%
+100.0%
Reduced / Exited
5 reduced · 6 sold out
SYRE
Spyre Therapeutics
10.8%
-16.7%
DNTH
Dianthus Therapeutics
3.5%
-30.3%
ORIC
Oric Pharmaceuticals
1.9%
-31.8%
KRRO
Korro Bio
0.2%
-56.1%
MAZE
Maze Therapeutics
2.0%
-3.5%
Apogee Therap…EXIT
Apogee Therapeutics
34.2%
Damora Therap…EXIT
Damora Therapeutics
2.8%
ELVNEXIT
Enliven Therapeutics
0.8%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.